Showing results (1-10 of 194) with videos related to
Sort By:
Pageof 20
Annals of Internal Medicine|October 3, 2022
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes statusMarat Fudim, Harriette G C Van SpallAnnals of Internal Medicine|January 6, 2025
In HF with mildly reduced or preserved ejection fraction, finerenone reduced worsening HF or CV death at 32 moMitra Chitsazan, Harriette G C Van Spall, Annals of Internal Medicine|June 6, 2022
In HF with mitral regurgitation, adding transcatheter mitral valve repair to medical therapy improved renal outcomes at 2 yKevin Damman, Harriette G C Van SpallAnnals of Internal Medicine|September 14, 2020
Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEFTauben Averbuch, Harriette G C Van SpallHeart Failure Reviews|May 26, 2026
Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art reviewHarriette G C Van Spall, Orly VardenyAnnals of Internal Medicine|September 4, 2023
SGLT2 inhibitors improved health status in Black and White patients with HF regardless of raceAmbarish Pandey, Harriette G C Van SpallAnnals of Internal Medicine|June 30, 2025
In HF with iron deficiency, IV ferric carboxymaltose did not reduce a composite of first HF hospitalization or CV death at a median 17 moDmitry Abramov, Harriette G C Van Spall, Annals of Internal Medicine|March 4, 2024
In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 moAhmad Masri, Harriette G C Van SpallAnnals of Internal Medicine|July 31, 2023
In adults with HF, opioids do not reduce refractory breathlessness (low-certainty evidence)Muhammad Shahzeb Khan, Harriette G C Van SpallAnnals of Internal Medicine|April 5, 2021
In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 yErsilia M DeFilippis, Harriette G C Van SpallPageof 20